drugset / Trial / NCT03125473
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
RandomizedParallel-groupOpen-labelPrevention
Summary
A Phase 1b, randomized, double-blind, dose-ranging trial to determine the safety of different dosing regimens an adenoviral-vector based norovirus vaccine (VXA-G1.1-NN) expressing GI.1 VP1 and dsRNA adjuvant administered orally to healthy volunteers
Timeline
- Start
- 2017-04-07
- Primary completion
- 2017-07-01
- Completion
- 2018-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VXA-G1.1-NN Oral Vaccine | Vaccine | 1 unknown | Oral |
| Subject | VXA-G1.1-NN Oral Vaccine | Vaccine | 6 unknown | Oral |